Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Eligibility criteria
Qualifiers
age > 18 years
surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Disqualifiers
systemic therapy received for non-glioblastoma tumor
Trial design
Treatments tested in this trial
- Relapsed glioblastoma
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
1CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale33000, Bordeaux France
Sponsors and collaborators
University Hospital, Bordeaux
Lead sponsor
Source ClinicalTrials.gov